遗传异质性
Wnt信号通路
生物
克拉斯
背景(考古学)
癌症研究
体内
生物信息学
恶性肿瘤
PI3K/AKT/mTOR通路
肝内胆管癌
表型
生物信息学
遗传学
突变
基因
医学
病理
信号转导
古生物学
作者
Nicholas T. Younger,Mollie L. Wilson,Anabel Martinez Lyons,Edward J. Jarman,Alison M. Meynert,Graeme R. Grimes,Konstantinos Gournopanos,Scott H. Waddell,Peter A. Tennant,David H. Wilson,Rachel Victoria Guest,Stephen J. Wigmore,Juan Carlos Acosta,Timothy James Kendall,Martin S. Taylor,Duncan Sproul,Pleasantine Mill,Luke Boulter
出处
期刊:Cancer Research
[American Association for Cancer Research]
日期:2022-01-24
卷期号:82 (8): 1548-1559
被引量:16
标识
DOI:10.1158/0008-5472.can-21-2556
摘要
Intrahepatic cholangiocarcinoma (ICC) is an aggressive malignancy of the bile ducts within the liver characterized by high levels of genetic heterogeneity. In the context of such genetic variability, determining which oncogenic mutations drive ICC growth has been difficult, and developing modes of patient stratification and targeted therapies remains challenging. Here we model the interactions between rare mutations with more common driver genes and combine in silico analysis of patient data with highly multiplexed in vivo CRISPR-spCas9 screens to perform a functional in vivo study into the role genetic heterogeneity plays in driving ICC. Novel tumor suppressors were uncovered, which, when lost, cooperate with the RAS oncoprotein to drive ICC growth. Focusing on a set of driver mutations that interact with KRAS to initiate aggressive, sarcomatoid-type ICC revealed that tumor growth relies on Wnt and PI3K signaling. Pharmacologic coinhibition of Wnt and PI3K in vivo impeded ICC growth regardless of mutational profile. Therefore, Wnt and PI3K activity should be considered as a signature by which patients can be stratified for treatment independent of tumor genotype, and inhibitors of these pathways should be levied to treat ICC. SIGNIFICANCE: This work shows that, despite significant genetic heterogeneity, intrahepatic cholangiocarcinoma relies on a limited number of signaling pathways to grow, suggesting common therapeutic vulnerabilities across patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI